May 11, 2023 07:35 AM EDTUpdated 11:17 AM
R&D

Take­da winds down Ther­a­vance pact, culls part­nered Crohn's pro­gram af­ter PhII flops

Katherine Lewin

News Reporter

Take­da re­vealed in its lat­est quar­ter fil­ing that it’s end­ing a sev­en-year al­liance with Ther­a­vance as the com­pa­nies fold a pro­gram that flopped in Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times